Received: 9 March 2020
Accepted: 24 April 2020
First Online: 27 May 2020
Ethics approval and consent to participate
: The Conjoint Health Research Ethics Board, University of Calgary, has reviewed and approved the research protocol with the ethics ID REB18–2045<i>.</i> Written informed consent to participate will be obtained from all participants or their parent or legal guardian as appropriate.
: Not applicable.
: SBF has received in-kind (study drug and placebo) support from GlaxoSmithKline and Novartis for the conduct of previous research evaluating the use of ondansetron; no support has been provided for the current study. SBF is also providing consulting services to RedHill Biopharm Ltd. The remaining authors declare no competing interests.